Filing Flows › Nutra Pharma (NPHC) › Q1 2025
Nutra Pharma (NPHC) Q1 2025 earnings results (first quarter 2025)
10-Q filed Mar 11, 2026
Nutra Pharma (NPHC) reported revenue of $74K for the first quarter 2025 (Q1 2025), +96% from a year earlier and -10% from the quarter before. Operating margin was -472.9%.
Nutra Pharma, Q1 2025: revenue $74K (+96% year over year), operating margin -472.9%, net loss $1.4M, operating cash flow −$405K. The chart follows the revenue to costs, profit and cash.
| Q1 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $74K | -10% | +96% |
| Operating profit | −$350K | — | — |
| Net earnings | −$1.4M | — | — |
| Operating cash flow | −$405K | — | — |
What changed
Revenue was $74K in Q1 2025, up 96% year over year and down 10% from the previous quarter.
Gross margin was 92.4%, down 0.9 points from a year earlier. Operating costs exceeded revenue by $350K, an operating margin of -472.9%. Operating expenses grew 27% against revenue growth of 96%. The quarter ended with a net loss of $1.4M, wider than the previous quarter's $231K loss. Net interest and other expense of $1.1M was the main reason.
Operating cash flow was −$405K. Non-cash charges added back $2K of depreciation. Working capital and other items added $1.0M. Capital expenditures of $26K exceeded it, leaving free cash flow of −$431K.
Questions
What was Nutra Pharma's revenue in the first quarter 2025?
Nutra Pharma (NPHC) reported revenue of $74K for the first quarter 2025 (Q1 2025), +96% from a year earlier and -10% from the quarter before.
Was Nutra Pharma profitable in the first quarter 2025?
Operating loss was $350K (-472.9% of revenue) and net loss $1.4M.
Source: Nutra Pharma 10-Q on SEC EDGAR.